生物标志物预测皮下低剂量II-2或免疫检查点抑制剂癌症免疫治疗疗效的临床研究

Oncogen Pub Date : 2019-03-14 DOI:10.35702/ONC.10009

L. P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G

{"title":"生物标志物预测皮下低剂量II-2或免疫检查点抑制剂癌症免疫治疗疗效的临床研究","authors":"L. P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G","doi":"10.35702/ONC.10009","DOIUrl":null,"url":null,"abstract":"1 Citation: Lissoni P (2019). A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors. Oncogen Journal 2(2): 9. A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors Lissoni P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose II-2 or with Immune Checkpoint Inhibitors\",\"authors\":\"L. P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G\",\"doi\":\"10.35702/ONC.10009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1 Citation: Lissoni P (2019). A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors. Oncogen Journal 2(2): 9. A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors Lissoni P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G\",\"PeriodicalId\":92827,\"journal\":{\"name\":\"Oncogen\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogen\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35702/ONC.10009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogen","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35702/ONC.10009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

引用本文:Lissoni P(2019)。预测皮下低剂量Il-2或免疫检查点抑制剂癌症免疫治疗疗效的生物标志物临床研究中华肿瘤杂志2(2):9。低剂量Il-2或免疫检查点抑制剂预测肿瘤免疫治疗疗效的生物标志物临床研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose II-2 or with Immune Checkpoint Inhibitors

1 Citation: Lissoni P (2019). A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors. Oncogen Journal 2(2): 9. A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors Lissoni P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncogen

自引率

0.00%

发文量